| Our unique mechanical
process has produced an amazing Concentrated Flax Hull Lignan
product. The result is 90% natural pure flax hulls yielding
the highest concentration of SDG lignans available in the
world. These flax hulls contain about 45-60 mg of SDG per
gram of finished product. This is approximately 7-8 times
more concentrated than ground flaxseed, is shelf stable, therefore
more effective than flax seed alone. Our competitors cannot
come close to the concentration of flax hull lignans that
are found in our lignan product.
Other sources of lignans such as rye, buckwheat,
millet, soy, and barley, yield 2-5 micrograms of lignans per
gram (mcg/g) of grain. Flaxseed yields an extraordinary 800
mcg/g of lignans.
Lignans were first discovered in flaxseeds in
the mid 1950's. The first interests in SDG's arose in the
mid 1980's. The lignan compounds have shown such extraordinary
potential that they have been studied by the National Cancer
Institute for their cancer preventative properties. The SDG
lignan not only has anti-cancer properties, it has anti-viral,
anti-bacterial, and anti-fungal properties. It is also a powerful
anti-oxidant. Most of the SDG’s tested for their anti-oxidant
activity have shown themselves to be 5 times greater in activity
than Vitamin E.
Products claiming "High Lignan Flax Seed
Oil" tested by the University of North Dakota have been
found to contain practically no lignans at all. That is expected
because the lignans are not in the oil; they are in the hull
of the seed.
"20% lignan particulates" does not
mean it contains 20% lignans, but it means 20% of the product
is made up of pieces of the flax fiber shell which does contain
the lignans. Since fiber meal contains 1.6% lignans, such
a product would contain about 0.35% lignans. If the product
is a liquid these particles will settle to the bottom and
no lignans will be consumed until you are the end of the bottle
unless it is always shaken well before it is poured.
Another product says "up to 30% more lignans
than the whole flax seed." This is essentially a product
consisting mostly of the defatted flax fiber without the oil.
There is no concentration or extract of lignans. Such a product
would thus contain about 1.5% lignans, which was the highest
level of lignans available until recently.
1. Adlercreutz H., et al. "Excretion
of the lignans enterolactone and enterodiol and of equol in
omnivorous and vegetarian postmenopausal women and in women
with breast cancer"
2. Bakke, J.E., and H.J. Kloesterman,
"A new diglucoside from flaxseed". Proceedings of
the North Dakota Academy of Science, 1956; 10:1 8-22
3. Adlercreutz, H., Mazur, W.
"Phyto-estrogens and Western Diseases" Ann. Med.,
19897,29(2):95-120 Prasad, K.
4: "Antioxidant Activity
of Secoisolariciresinol Diglycoside derived Metabolites, Secoisolariciresinol,
Enterodiol, and Enterolactone" Int. Journal of Oncology,
2000 Oct. 9:220-225
In vitro (test tube) and animal studies have
suggested that the lignans in flaxseed may reduce breast carcinogenesis
and metastasis (ability of cancer cells to migrate to other
parts of the body) (1, 2). Women who develop breast cancer
generally have a 10-20% higher concentration of the estrogen
hormone estradiol (3). This suggests that the reported anti-estrogenic
activity of flaxseed-derived lignans may be health protective
in women who have high circulating levels of this hormone.
Also, it has been suggested that a high intake of dietary
fiber, such as that found in flaxseed, may reduce the risk
of cancer by increasing the excretion of carcinogenic bile
salts from the colon (4). A randomized, controlled clinical
trial of 10g/day ground flaxseed in postmenopausal women showed
an increase of the urinary ratio of 2-hydroxyestrogen (2-OH)
to 16-á-hydroxyestrogen (16-á-OH) estrogen metabolites,
as well as an increase in 2-OH metabolites alone; both of
these ratio alterations are considered to be protective against
breast cancer (5). Another randomized controlled clinical
trial reported a significant, dose-dependent reduction of
serum 17â-estradiol in postmenopausal women who supplemented
with 5-10 grams per day of flaxseed (3). Since epidemiological
studies show approximately 10% increases in 17â-estradiol
in breast cancer patients, these findings may indicate a protective
effect (3).
When flaxseeds are consumed, their plant lignans,
secoisolariciresinol diglycoside (SDG) and matairesinol diglycoside
(MDG), are converted in the body to the mammalian lignans,
enterodiol and enterolactone; women with a history of breast
cancer have significantly lower levels of enterodiol and enterolactone
than women without cancer (6, 7). Additionally, lignans can
exert anti-estrogenic effects when circulating levels of estrogen
are raised, and lifetime estrogen exposure has been linked
to risk of breast cancer. The combination of these findings
suggests that plant lignans may reduce the risk of estrogen-related
breast cancer (6, 7). In addition to the effects of lignans,
the fiber found in flaxseeds may help to remove estrogen,
as well as other potentially carcinogenic compounds, from
the body (8, 4).
Clinical research has suggested that flaxseeds
may beneficially alter levels of compounds that are used as
markers for risk of breast cancer development. An increased
ratio of the estrogen metabolites 2-hydroxyestrogen (2-OH)
to 16-alpha-hydroxyestrogen (16-á-OH) has been suggested
to be preventive against breast cancer. In clinical trials,
5-10 grams of daily ground flaxseed consumption has been shown
to increase the 2-OH: 16-á-OH ratio (8, 5. High levels
of serum17â-estradiol may be another biomarker for increased
breast cancer risk, as epidemiological studies have shown
an approximately 10% increase in serum 17â-estradiol
in breast cancer patients; a randomized, controlled, clinical
trial in postmenopausal women supplemented with 5-10 grams
per day of ground flaxseed for 7 weeks reported a significant,
dose-dependent reduction of serum 17â-estradiol (7).
Flaxseeds have also been beneficial in treating
breast cancer in animals. A reduction in breast tumor growth,
as well as reductions in levels of compounds involved in tumor
growth and metastasis (cancer cells spreading throughout the
body), have been shown to occur after supplementing with flaxseeds
and/or plant lignan extracts (2, 9). Additionally, breast
cancer cells treated with purified enterodiol and enterolactone
have been shown to have a reduced ability to metastasize (1).
This effect of flaxseed is similar to that of the breast cancer
drug, Tamoxifen. The positive effects of flaxseed in these
studies have been shown both in breast cancers that express
estrogen receptors and in those that do not, suggesting that
these effects may be mediated through estrogen-like lignan
activity and also by some other, still to be determined, physiological
mechanism.(1).
The information presented here is for informative
and educational purposes only and is not intended as curative
or prescriptive advice.
Bibliography
1. Chen J, Thompson LU. Lignans
and tamoxifen, alone or in combination, reduce human breast
cancer cell adhesion, invasion and migration in vitro. Breast
Cancer Res Treat 2003;80(2):163-70.
2. Dabrosin C, Chen J, Wang L,
Thompson LU. Flaxseed inhibits metastasis and decreases extracellular
vascular endothelial growth factor in human breast cancer
xenografts. Cancer Lett 2002;185(1):31-7.
3. Hutchins AM, Martini MC, Olson
BA, Thomas W, Slavin JL. Flaxseed consumption influences endogenous
hormone concentrations in postmenopausal women. Nutr Cancer
2001;39(1):58-65.
4. Adlercreutz H. Does fiber-rich
food containing animal lignan precursors protect against both
colon and breast cancer? An extension of the "fiber hypothesis".
Gastroenterology 1984; 86(4):761-4.
5. Haggans CJ, Hutchins AM, Olson
BA, Thomas W, Martini, MC, Slavin JL. Effect of flaxseed consumption
on urinary estrogen metabolites in postmenopausal women. Nutr
Cancer 1999; 33(2):188-95.
6. Adlercreutz H, Fotsis T, Heikkinen
R, Dwyer JT, Woods M, Goldin BR et al. Excretion of the lignans
enterolactone and enterodiol and of equol in omnivorous and
vegetarian postmenopausal women and in women with breast cancer.
Lancet 1982;2(8311):1295-9.
7. 58-65.
8. Haggans CJ, Travelli EJ, Thomas
W, Martini MC, Slavin JL. The effect of flaxseed and wheat
bran consumption on urinary estrogen metabolites in premenopausal
women. Cancer Epidemiol Biomarkers Prev 2000;9(7):719-25.
9. Thompson LU, Rickard SE, Orcheson
LJ, Seidl MM. Flaxseed and its lignan and oil components reduce
mammary tumor growth at a late stage of carcinogenesis. Carcinogenesis
1996;17(6):1373-6. |